Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 11, 2021 at 10:52 AM.

  1. #1 cafead, Jun 11, 2021 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.

    article source
     
    Quote

Reply to Thread